ASIA-PACIFIC IBS-C DRUG MARKET FORECAST 2017-2025

July 2017 | 58 pages | ID: A2AD3FE210EEN
Inkwood Research

Abstracts

KEY FINDING

The Asia-Pacific IBS-c drug market is predicted to grow at a CAGR of 6.29% over the forecast period of 2017-2025 and generate an estimated revenue of 210.28 million by the end of 2025. The high unmet needs for the drugs in the Asian region leading to a subsequent higher demand from the market are expected to boost the market growth in the coming years

MARKET INSIGHTS

IBS being a heritable condition in some of the population, the poor and unhealthy eating habits and the pipeline drugs in the market are some of the major drivers for the Asian IBS-c drug market. The market is segmented according to the prescription type and drug type. The prescription type is further classified into over the counter drugs and prescription drugs, with the over the counter drugs being more popular in the market. The drug type segment contains Stimulant Laxatives, Osmotic Laxatives, Lubiprostone, Linaclotide, and some pipeline drugs such as plecanatide. Of these, lubiprostone currently has the highest market share in the market. However, the change in lifestyle and the use of alternate natural ways to cure IBS might prove challenging for the market in the future.

COMPETITIVE INSIGHTS

Some of the major companies in the region are:

• Norgine B.V.
• Prometheus Laboratories Inc.
• Actavis Nordic A/S
• Albireo Pharma Inc
• Yuhan Corp
• Astrazeneca Plc
• The Menarini Group
• Ono Pharmaceutical Co., Ltd.

Contents

1. RESEARCH SCOPE

1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

2.1. SOURCES OF DATA
  2.1.1. SECONDARY DATA
  2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY

4. MARKET OVERVIEW

4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
4.5. DRIVERS
  4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
  4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
  4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
  4.5.4. IBS CAN BE A HERITABILITY ISSUE
  4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
4.6. RESTRAINTS
  4.6.1. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
  4.7.1. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
  4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
  4.8.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS

5. ASIA PACIFIC IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)

5.1. OVERVIEW
  5.1.1. LUBIPROSTONE
  5.1.2. LINACLOTIDE
  5.1.3. STIMULANT LAXATIVES
  5.1.4. OSMOTIC LAXATIVES
  5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION
5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)

6. ASIA PACIFIC IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

6.1. PRESCRIBED DRUGS
  6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
  6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

7.1. PORTERS FIVE FORCE ANALYSIS
  7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
  7.1.2. BARGAINING POWER OF SUPPLIERS
  7.1.3. BARGAINING POWER OF BUYERS
  7.1.4. THREAT OF SUBSTITUTE PRODUCTS
  7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX

8. ASIA PACIFIC IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)

8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC

9. COMPANY PROFILES

9.1. CATALENT PHARMACEUTICALS SOLUTIONS
  9.1.1. OVERVIEW
  9.1.2. PRODUCT PORTFOLIO
  9.1.3. SCOT ANALYSIS
  9.1.4. STRATEGIC MOVES
9.2. NESTLE
  9.2.1. OVERVIEW
  9.2.2. PRODUCTS PORTFOLIO
  9.2.3. SCOT ANALYSIS
  9.2.4. STRATEGIC MOVES
9.3. ABBOTT LABORATORIES
  9.3.1. OVERVIEW
  9.3.2. PRODUCT PORTFOLIO
  9.3.3. SCOT ANALYSIS
  9.3.4. STRATEGIC MOVES
9.4. SYNERGY PHARMACEUTICALS
  9.4.1. OVERVIEW
  9.4.2. PRODUCTS PORTFOLIO
  9.4.3. SCOT ANALYSIS
  9.4.4. STRATEGIC MOVES
9.5. SUCAMPO PHARMACEUTICALS
  9.5.1. OVERVIEW
  9.5.2. PRODUCT PORTFOLIO
  9.5.3. SCOT ANALYSIS
  9.5.4. STRATEGIC MOVES
9.6. NOVARTIS PHARMA AG
  9.6.1. OVERVIEW
  9.6.2. PRODUCTS PORTFOLIO
  9.6.3. SCOT ANALYSIS
  9.6.4. STRATEGIC MOVES
9.7. ASTELLAS PHARMACEUTICALS
  9.7.1. OVERVIEW
  9.7.2. PRODUCT PORTFOLIO
  9.7.3. SCOT ANALYSIS
  9.7.4. STRATEGIC MOVES
9.8. ARDELYX, INC.
  9.8.1. OVERVIEW
  9.8.2. PRODUCT PORTFOLIO
  9.8.3. SCOT ANALYSIS
  9.8.4. STRATEGIC MOVES
9.9. SYNTHETIC BIOLOGICS, INC.
  9.9.1. OVERVIEW
  9.9.2. PRODUCT PORTFOLIO
  9.9.3. SCOT ANALYSIS
  9.9.4. STRATEGIC MOVES
9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  9.10.1. OVERVIEW
  9.10.2. PRODUCT PORTFOLIO
  9.10.3. SCOT ANALYSIS
  9.10.4. STRATEGIC MOVES
9.11. BAMA-GEVE, SLU
  9.11.1. OVERVIEW
  9.11.2. PRODUCT PORTFOLIO
  9.11.3. SCOT ANALYSIS
9.12. FERRING BV
  9.12.1. OVERVIEW
  9.12.2. PRODUCT PORTFOLIO
  9.12.3. SCOT ANALYSIS
  9.12.4. STRATEGIC MOVES
9.13. IRONWOOD PHARMACEUTICALS, INC.
  9.13.1. OVERVIEW
  9.13.2. PRODUCT PORTFOLIO
  9.13.3. SCOT ANALYSIS
  9.13.4. STRATEGIC MOVES
9.14. SALIX PHARMACEUTICALS LTD
  9.14.1. OVERVIEW
  9.14.2. PRODUCT PORTFOLIO
  9.14.3. SCOT ANALYSIS
  9.14.4. STRATEGIC MOVES
9.15. NORGINE B.V.
  9.15.1. OVERVIEW
  9.15.2. PRODUCT PORTFOLIO
  9.15.3. SCOT ANALYSIS
  9.15.4. STRATEGIC MOVES
9.16. PROMETHEUS LABORATORIES INC.
  9.16.1. OVERVIEW
  9.16.2. PRODUCT PORTFOLIO
  9.16.3. SCOT ANALYSIS
  9.16.4. STRATEGIC MOVES
9.17. ACTAVIS NORDIC A/S
  9.17.1. OVERVIEW
  9.17.2. PRODUCT PORTFOLIO
  9.17.3. SCOT ANALYSIS
  9.17.4. STRATEGIC MOVES
9.18. ALBIREO PHARMA INC
  9.18.1. OVERVIEW
  9.18.2. PRODUCT PORTFOLIO
  9.18.3. SCOT ANALYSIS
  9.18.4. STRATEGIC MOVES
9.19. YUHAN CORP
  9.19.1. OVERVIEW
  9.19.2. PRODUCT PORTFOLIO
  9.19.3. SCOT ANALYSIS
  9.19.4. STRATEGIC MOVES
9.20. ASTRAZENECA PLC
  9.20.1. OVERVIEW
  9.20.2. PRODUCT PORTFOLIO
  9.20.3. SCOT ANALYSIS
  9.20.4. STRATEGIC MOVES
9.21. THE MENARINI GROUP
  9.21.1. OVERVIEW
  9.21.2. PRODUCT PORTFOLIO
  9.21.3. SCOT ANALYSIS
  9.21.4. STRATEGIC MOVES
9.22. ONO PHARMACEUTICAL CO., LTD.
  9.22.1. OVERVIEW
  9.22.2. PRODUCT PORTFOLIO
  9.22.3. SCOT ANALYSIS
  9.22.4. STRATEGIC MOVES

List Of Tables

LIST OF TABLES

TABLE 1 ASIA PACIFIC IBS-C MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
TABLE 4 POPULATION OF ASIA BY AGE GROUP IN VARIOUS SUB REGION, JULY 2013
TABLE 5 ASIA PACIFIC IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PRODUCT PROFILE (SENNA)
TABLE 10 PRODUCT PROFILE (LACTULOSE)
TABLE 11 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 12 PRODUCT PROFILE (PSYLLIUM)
TABLE 13 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 14 ASIA PACIFIC IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 15 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 ASIA PACIFIC IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 ASIA PACIFIC IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
FIGURE 3 ASIA PACIFIC IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 DIETS RESPONSIBLE FOR IBS
FIGURE 5 DRUGS PULLED OFF FROM THE MARKET
FIGURE 6 LIFESTYLE AND HOME REMEDIES FOR IBS
FIGURE 7 CHINA IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 8 CHINESE MEDICINE TCM TREATMENT FOR IBS
FIGURE 9 JAPAN IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
FIGURE 10 PHARMACEUTICAL MARKET SALES
FIGURE 11 REST OF APAC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)